drugset
drugset / Trial / NCT02940132

A Study of SC10914 in Patients With Advanced Solid Tumors

NCT02940132 ↗

Phase 1 Unknown 72 enrolled Jiangxi Qingfeng Pharmaceutical Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

SC10914 is a potent selective PARP-1 and PARP-2 inhibitor. This study aims to determine the safety , tolerability , pharmacokinetic/pharmacodynamics profile of increasing doses of SC10914 when administered orally to patients with advanced solid tumors. Furthermore, the safety and efficacy of SC10914 in patients with advanced solid tumors and negative expression of ATM or BRCA1 or BRCA2 mutation will be evaluated in expanded cohorts to establish the Recommended Phase 2 Dose(RP2D).

Timeline

Start
2016-10
Primary completion
2018-03
Completion
2018-05

Drugs

EvaluationDrugModalityDoseRoute
Subject SC10914 Unknown 30 mg Oral
Subject SC10914 Unknown 60 mg Oral
Subject SC10914 Unknown 100 mg Oral
Subject SC10914 Unknown 120 mg Oral
Subject SC10914 Unknown 150 mg Oral
Subject SC10914 Unknown 200 mg Oral
Subject SC10914 Unknown 300 mg Oral
Subject SC10914 Unknown 400 mg Oral

Indications

cancer